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Abstract 
 
The human matrix metalloproteinase (MMP) gene family includes 24 genes whose regulated 
expression, together with that of four tissue inhibitors of metalloproteinases (TIMPs), is essential 
in tissue remodelling and cell signalling. Quantitative real-time-PCR (qPCR) analysis was used 
to evaluate the shared and unique patterns of control of these two gene families in human MRC-5 
and WI-38 fibroblasts in response to the protein kinase C (PKC) activator phorbol-12-myristate-
13-acetate (PMA). The requirement for ongoing translation was analysed using three protein 
synthesis inhibitors, anisomycin, cycloheximide and emetine. PMA induced MMP1, 3, 8, 9, 10, 
12, 13, 14 and TIMP1 and TIMP3 RNAs after 4-8 hours, and induction of all except MMP9 and 
TIMP3 was blocked by all protein synthesis inhibitors. However, even though all inhibitors 
effectively blocked translation, PMA-induction of MMP9 and TIMP3 was blocked by emetine 
but was insensitive to cycloheximide and anisomycin. Anisomycin alone induced MMP9 and 
TIMP3, along with MMP25 and MMP19. The extracellular signal-regulated kinase (ERK)-1/2 
were strongly activated by PMA, while anisomycin activated the c-Jun N-terminal kinase (JNK) 
and p38 pathways, and cycloheximide activated p38, but emetine had no effect on the stress-
activated mitogen-activated protein kinase (MAPK) pathways. The involvement of the p38 and 
JNK pathways in the selective effects of anisomycin and cycloheximide on MMP/TIMP 
expression was supported by use of pharmacological inhibitors. These data confirm that most 
inducible MMPs and TIMP1 behave as “late” activated, protein synthesis-dependent genes in 
fibroblasts. However, the requirement of protein synthesis for PMA-induction of MMPs and 
TIMPs is not universal, since it is abrogated for MMP9 and TIMP3 by stimulation of the stress-
activated MAPK pathways. The definition of clusters of co-regulated genes among the two gene 
families will aid in bioinformatic dissection of control mechanisms.   
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1. Introduction 
 
The matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) constitute an 
extracellular proteolytic system whose coordination is critical for development, homeostasis and 
repair following injury. The human MMP family comprises 24 zinc-dependent endopeptidases 
that degrade components of the extracellular matrix (ECM) and also execute precise regulatory 
cleavages on components of growth factor, cytokine and chemokine signaling networks (Chang 
and Werb, 2001; Egeblad and Werb, 2002; López-Otín and Overall, 2002; Puente et al., 2003). Their 
activities are tightly controlled, with dysregulation being observed in numerous pathological 
states such as cancer, arthritis and cardiovascular disease. Regulation of MMP activity occurs at 
different levels, including gene transcription, post-transcriptional mRNA stabilization, 
translational efficiency, enzyme compartmentalization and secretion, zymogen activation and 
inhibition of the active enzyme by four TIMPs (Overall and López-Otín, 2002; Edwards et al., 1987; 
Edwards et al., 1992; Baker et al., 2002). To understand proteolytic control at the cellular level, it is 
therefore important to identify the shared and unique mechanisms that are employed to control 
the output from these two functionally interconnected gene families. 
 
Signal-dependent activation and repression of gene transcription is the principal level of control 
for several MMP and TIMP genes (Baker et al., 2002; Yan and Boyd, 2007), with involvement of 
the mitogen-activated protein kinase (MAPK), nuclear factor-κB and Smad-dependent pathways 
(Overall and López-Otín, 2002; Baker et al., 2002; Borden and Heller, 1997; Westermarck et al., 2001; 
Vincenti and Brinckerhoff, 2002; Reunanen et al., 2002; Hall et al., 2003). The three major MAPK 
pathways have all been implicated in MMP/TIMP gene control (Baker et al., 2002; Vincenti and 
Brinckerhoff, 2002; Reunanen et al., 2002). These pathways are the extracellular signal-regulated 
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kinase (ERK)-1/2 pathway [Raf→ MAP/ERK (MEK)-1/2→ ERK-1/2] that is activated by 
mitogens via Ras and by phorbol esters via protein kinase C (PKC), and the c-Jun N-terminal 
kinase (JNK) pathway [MEK-1/3→ MAPK kinase (MKK)-4/7→ JNK-1/2/3] and p38 [MAPK 
kinase kinase (MAPKKK) →MKK3/6→p38 α, β, γ, δ] pathways that are activated by oxidative 
stress, inflammatory cytokines, ultraviolet irradiation and certain protein synthesis inhibitors 
such as anisomycin and cycloheximide (Westermarck et al., 2001; Cano and Mahadevan, 1995; 
Pearson et al., 2001; Hazzalin and Mahadevan, 2002; Yang et al., 2003). Acting either directly or 
indirectly through downstream kinases, activated MAPKs induce phosphorylation of 
transcription factors and co-activators (Westermarck et al., 2001; Vincenti and Brinckerhoff, 2002; 
Pearson et al., 2001) and also target nucleosomal proteins leading to transcriptional activation of a 
class of genes termed “immediate early” (IE) genes (reviewed in Hazzalin and Mahadevan, 2002), 
which include the c-fos and c-jun families that comprise the Activator Protein 1 (AP1) 
transcription factor complex. AP1-binding sites are present in the promoter regions of many 
MMP and TIMP genes often collaborating with PEA3 elements in gene induction (Overall and 
López-Otín, 2002; Edwards et al., 1987; Edwards et al., 1992; Baker et al., 2002; Vincenti and 
Brinckerhoff, 2002; Hall et al., 2003; Auble and Brinckerhoff, 1991). Indeed, it is well-established that 
AP1 factors are essential for the transcriptional activation of several MMP and TIMP genes in 
response to inducing stimuli, including MMP1, MMP3 and TIMP1 (McDonnell et al., 1990; Hu et 
al., 1994). 
 
The defining characteristics of IE genes are that they are rapidly and transiently activated as a 
primary response to growth factors, phorbol-12-myristate-13-acetate (PMA), stress and 
inflammatory mediators, and this occurs without a requirement for new protein synthesis. In fact, 
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protein synthesis inhibitors in combination with growth factors or phorbol esters evoke super-
induction of IE transcripts (Edwards and Mahadevan, 1992; Cano et al., 1994; reviewed in Hazzalin 
and Mahadevan, 2002). In contrast, MMP and TIMP genes are generally considered to be “late”-
activated genes, since their transcripts are usually induced over a timecourse of several hours, 
and for a few (eg MMP3, TIMP1) a requirement for protein synthesis has been documented 
(McDonnell et al., 1990; Matrisian et al., 1986; Edwards et al., 1985). However, there has been no 
systematic evaluation of the basic induction kinetics of the MMP and TIMP family members, 
which is necessary as a prelude to understanding their regulatory circuitry. 
 
In the present study, we have used quantitative real-time-PCR (qPCR) technology to analyze the 
responses of the entire MMP and TIMP families in human fibroblasts following activation by a 
model stimulus, PMA, which activates PKC and mimics the effect of both growth factors and 
cytokines (Toullec et al., 1991; reviewed in Pearson et al., 2001 and Borden and Heller, 1997). Three 
potent inhibitors of translation (anisomycin, emetine and cycloheximide) were used to 
discriminate genes that display late versus IE activation characteristics. As anticipated, PMA 
induced a subset of MMP and TIMP genes and emetine blocked induction, consistent with the 
identification of these genes as late-activated. However, in addition to their effects on translation, 
anisomycin and cycloheximide (but not emetine) elicited differential activation of the main 
MAPK pathways, with anisomycin strongly and selectively activating both JNK and p38 and 
cycloheximide activating p38. These effects on the p38 and JNK pathways did not obscure the 
strict dependency on de novo protein synthesis shown by most PMA-responsive MMPs and 
TIMPs, but for TIMP3 and MMP9 the requirement was by-passed. Moreover, anisomycin itself 
potently induced selected MMPs and TIMP3 mainly via p38 and/or JNK. These data provide the 
 6 
first comprehensive dissection of the induction machinery of the MMP and TIMP gene families. 
As a corollary, they emphasize the importance of consideration of effects on both signaling and 
translation when using protein synthesis inhibitors as tools in cell-based investigations. 
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2. Results 
 
2.1 Relative mRNA levels and PMA-responsiveness of the entire MMP and TIMP family in 
MRC-5 fibroblasts.  
Initially we undertook qPCR analysis of the expression of every MMP and TIMP gene in human 
MRC-5 fibroblasts under basal (serum-starved) conditions and at different times after PMA 
stimulation, ranging from 30 minutes to 12 hours. Unstimulated MRC-5 cells expressed all four 
TIMPs and 20 MMPs. Note that MMP23A and MMP23B sequences are identical (reviewed in 
Overall and López-Otín, 2002) and thus are recorded as a single output, MMP23. Using the CT as 
an indicator of relative expression levels, 12 MMPs and all 4 TIMPs were expressed under 
serum-free conditions at high-very high levels, while 8 MMPs are moderately expressed or 
present at low levels; transcripts for MMP9, MMP13 and MMP20 were undetectable (Table 1). 
Following PMA stimulation, 8 MMP genes (MMP1, MMP3, MMP8-10, MMP12-14) and TIMP1 
and TIMP3 showed strong induction that was maximal at the 8 or 12 hours time points. The only 
gene not expressed in either basal or PMA-stimulated conditions was MMP20. No MMP or 
TIMP genes were induced at 30 minutes following PMA treatment, though c-fos and c-jun and 
other IE genes showed robust activation (data not shown). Also no genes showed any reduction 
in expression levels. The same pattern of gene induction and responsiveness was seen in human 
WI-38 fibroblasts (data not shown). From this initial profile it was apparent that the PMA-
inducible MMPs and TIMPs are temporally late-activated genes in human fibroblasts. For 
subsequent experiments analyzing requirements for ongoing translation for gene induction we 
used a single 8 hours timepoint since this allowed all the inducible genes to be easily quantified. 
 
 8 
2.2 Effects of protein synthesis inhibitors on the expression and PMA-induction of MMP 
and TIMP genes.  
We used three protein synthesis inhibitors (anisomycin, cycloheximide and emetine) that act by 
different mechanisms (Edwards and Mahadevan, 1992; Cano et al., 1994). Up to 8 hours of treatment 
each inhibitor blocked translation by at least 92% in quiescent and PMA-stimulated MRC-5 
cells, as determined by 3H-Leucine incorporation (Fig. 1A). At this time point cell viability (as 
determined by MTT assay) was reduced by no more than 18% for any inhibitor, though this 
increased at longer exposures (data not shown). 
 
We then examined the effects of protein synthesis inhibition on the expression of the MMP and 
TIMP genes under basal conditions and following PMA-stimulation. Given the delayed 
timeframe over which the PMA-induction of MMP and TIMP transcripts was apparent, our 
initial hypothesis was that translational arrest would block activation of the inducible genes, as 
has been previously demonstrated for MMP1, MMP3, and TIMP1 (Overall et al., 1991; Matrisian et 
al., 1986; Edwards et al., 1985). However, using k-means clustering by Spearman rank correlation 
(Eisen et al., 1998) we identified four distinct groups of genes according to their response to PMA 
and/or protein synthesis inhibitors. Genes in group I were defined as PMA-responsive, while all 
protein synthesis inhibitors blocked the PMA-induction, but had no effect when used alone. 
These genes are: MMP1, 3, 8, 10, 12, 13, 14 and TIMP1 (see representative patterns of 
expression of MMP1 and TIMP1 genes of this group in Fig. 1B and 1C). Genes in group II were 
induced by both PMA and anisomycin alone, but not by emetine and cycloheximide. These 
genes were TIMP3 and MMP9 (the TIMP3 pattern is shown in Fig. 1D). For both of these genes, 
the PMA-induction was not impaired by either anisomycin or cycloheximide, but was reduced by 
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emetine. A third pattern was displayed by MMP25, which is the only gene in group III: it was 
induced by anisomycin but not by PMA, emetine or cycloheximide (Fig. 1E). The combination 
of anisomycin and PMA led to a superinduction of MMP25 while cotreatment of PMA with 
emetine or cycloheximide also induced MMP25 to the same extent as anisomycin alone (Fig. 
1E). Finally, MMP19 is the only gene in group IV, which was anisomycin-, emetine- and 
cycloheximide-responsive, but PMA-unresponsive (Fig. 1F). In the presence of PMA the 
translation inhibitors continued to induce MMP19 transcripts, and the combination of PMA and 
emetine consistently further enhanced MMP19 transcript accumulation. The effect of PMA and 
protein synthesis inhibitors used alone or in combination had an almost identical effect on MMP 
and TIMP expression in WI-38 fibroblasts compared to MRC-5 cells: with the exception of 
MMP8 and MMP14 all genes showed a positive Spearman correlation coefficient (rs >0.5) with p 
<0.05. This indicates that the effect of PMA and protein synthesis inhibitors is not specific for 
MRC-5. 
 
These data indicate that the responses of the MMP and TIMP genes to translational inhibitors is 
more complex than previously recognized, with only the genes of group I corresponding to the 
pattern expected of typical late-activated, protein synthesis-dependent genes. The other three 
categories indicate selective effects on gene expression as a result of either the mode of 
translational arrest or a secondary action of particular inhibitors. Since it is recognized that 
anisomycin and cycloheximide can exert effects on MAPK signaling (Edwards and Mahadevan, 
1992; Cano et al., 1994), we next investigated in detail the impact of all three protein synthesis 
inhibitors on the status of the ERK, p38 and JNK MAPK pathways in MRC-5 cells. 
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2.3 Effects of PMA and protein synthesis inhibitors on the main MAPKs in MRC-5 
fibroblasts.  
The protein synthesis inhibitors used in these studies cause translational arrest through distinct 
mechanisms: anisomycin and cycloheximide bind to the 60S ribosomal subunit whereas emetine 
targets the 40S subunit, though all three block elongation of the nascent peptide chain and cause 
polysome stabilization (Edwards and Mahadevan, 1992). An additional inhibitor, puromycin, is 
an analogue of the 3’ end of the aminoacyl tRNA that interacts with site A on the 60S ribosomal 
subunit causing polysome disaggregation. Previous studies have shown that protein synthesis 
inhibitors differentially activate cell signaling pathways independent of their ability to block 
translation (Mahadevan and Edwards, 1991; Edwards and Mahadevan; 1992). We investigated 
the activation patterns of the main MAPKs (ERK-1/2, JNK and p38) in response to PMA and 
anisomycin, emetine, and cycloheximide by western blot analysis using antibodies against 
activated and total forms of these MAPKs. Under basal conditions there were detectable levels of 
p-ERK-1/2 in MRC-5 cells, although exposure to PMA resulted in rapid activation by as early as 
5 minutes and the response was sustained for at least 60 minutes (Fig. 2). PMA did not cause 
appreciable activation of JNK and p38 during this time course (Fig. 2). The apparent phospho-
p38 signals in Fig. 2 in response to PMA reflect a low and variable background level; likewise 
no induction by PMA was observed in WI-38, C3H10T½ and 3T3 cells (data not shown). 
Exposure of MRC-5 cells to anisomycin resulted in activation of p38 and JNK within 5 and 15 
minutes respectively, and the inductions were maintained up to 60 minutes (Fig. 2). 
Cycloheximide activated p38 from 5 minutes of incubation, but did not activate the JNK 
pathway appreciably, while emetine (Fig. 2) and also puromycin (data not shown) had no 
appreciable effect on MAPK signaling at time points up to 60 minutes (though 4 hours treatment 
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with emetine activated ERK, JNK and p38 in mouse C3H10T½ cells, D. Young, unpublished 
observation). Overall, the same pattern of effects of PMA, anisomycin, emetine and 
cycloheximide on MAPK activation were observed in WI-38 fibroblasts (data not shown). 
 
A major finding from the above data is that translation inhibitors differentially activate the main 
MAPK pathways in human fibroblasts, with both anisomycin and cycloheximide activating p38, 
and anisomycin alone strongly activating JNK-1/2, and emetine having minimal effects. This 
may shed light on the differential effects of translation inhibitors on the MMP and TIMP genes 
comprising groups II and III discussed above. For Group II (TIMP3 and MMP9), the pattern of 
responses suggests that the activation of p38 signaling by anisomycin and cycloheximide might 
obviate the requirement for new protein synthesis for PMA-induction, which is manifest when 
emetine is used to arrest translation. On this basis, the strong selective activation of JNK-1/2 by 
anisomycin alone may be responsible for induction of these genes in the absence of PMA, and 
the induction of the group III gene (MMP25) by anisomycin alone (Fig. 2). 
 
 
2.4 Effect of pharmacological inhibitors on selected MMP and TIMP genes in MRC-5 cells. 
A logical extension of our studies was to assess the impact of selective pharmacological 
inhibitors U0126, SB 203580 and SP600125 that inhibit the activity of ERK-1/2, p38 and JNK-
1/2 respectively (reviewed in Pearson et al., 2001), in order to link MAPK activity to gene 
induction responses to PMA and anisomycin. In addition, we treated cells with 
Bisindolylmaleimide I, a specific inhibitor of PKC (Toullec et al., 1991), to establish the PKC-
dependence of MMP and TIMP in response to PMA. MRC-5 fibroblasts were serum-starved for 
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18 hours, followed by treatment with U0126, SB 203580, SP600125 or Bisindolylmaleimide I 
for 30 minutes and then stimulated with PMA or anisomycin for 8 hours. Cell viability, as 
assessed by MTT analysis, in MRC-5 and WI-38 was reduced by less than 10% by anisomycin 
and PMA used alone or in combination with pharmacological inhibitors (data not shown). 
 
As anticipated, the PKC inhibitor Bisindolylmaleimide I suppressed the PMA-responsiveness of 
all PMA-inducible genes (Fig. 3 and data not shown). The ERK-1/2 activation inhibitor U0126 
suppressed the PMA-responsiveness (p <0.05) of MMP1 (Fig. 3A), MMP10 (Fig. 3B), TIMP1 
(Fig. 3C) and TIMP3 (Fig. 3D), this was also the case for MMP3, MMP8, MMP9, MMP12, 
MMP13 and MMP14 (data not shown), U0126 did not affect significantly (p >0.05) the 
anisomycin induction of TIMP3 (Fig. 3D), MMP25 (Fig. 3E) and MMP19 (Fig. 3F). These data 
demonstrate that the effect of PMA, but not anisomycin, is mediated via ERK-1/2 activation to 
induce the expression of select MMP and TIMP genes. 
 
The p38 inhibitor SB 203580 did not block PMA-responsiveness (p >0.05) of any gene 
stimulated by PMA (Fig. 3A, B, C, D and data not shown), suggesting that PMA-responsiveness 
does not act through this MAPK pathway. However SB 203580 suppressed the anisomycin 
induction of MMP25 (p <0.001; Fig. 3E), but stimulated the anisomycin induction of MMP19 (p 
<0.001; Fig. 3F). The TIMP3 induction by anisomycin was somewhat reduced by SB 203580 
however this was not a significant difference (p >0.05; Fig. 3D). The JNK inhibitor SP600125 
did not block PMA-responsiveness (p >0.05) of any gene analyzed with the exception of TIMP3 
(p <0.05; Fig. 3D). Interestingly, for MMP10, SP600125 consistently had a synergistic effect 
with PMA (p <0.01; Fig. 3B). This inhibitor suppressed anisomycin induction of TIMP3 (p 
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<0.05; Fig. 3D), MMP25 (p <0.001; Fig. 3E) and MMP19 (p <0.001; Fig. 3F), suggesting a role 
for JNK in mediating anisomycin induction of selected MMP genes and TIMP3. 
 
In the same experiments we also analyzed MMP2 expression since our previous data had shown 
this gene was not affected by PMA or protein synthesis inhibitors. Pharmacological inhibition of 
MAPK and PKC in the presence or absence of PMA or anisomycin had no significant effect on 
MMP2 expression in MRC-5 or WI-38 cells (data not shown). 
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3. Discussion 
 
The human MMP and TIMP genes have arisen via successive gene duplication events during 
early vertebrate evolution (Huxley-Jones et al., 2007), and in the process have acquired gene-
specific functions and regulatory mechanisms. We have carried out the first comprehensive 
analysis of the human MMP and TIMP families with regard to basic patterns of gene regulation 
in human fibroblasts. Our data identify gene groupings that share aspects of regulation, with one 
group in particular comprising the collagenases, stromelysins and TIMP1, which are recognized 
as key factors in connective tissue remodeling. These group I genes (MMP1, 3, 8, 10, 12-14 and 
TIMP1) are typical “late”-activated genes in response to PMA in fibroblasts, whose induction 
occurs several hours after stimulation and requires ongoing protein synthesis. However, in 
addition to genes that were silent (MMP20) or expressed at constitutive levels (MMP2, 11, 15-
17, 21, 23, 24-28, TIMP2 and TIMP4), we found three other patterns of inducible responses to 
PMA and protein synthesis inhibitors displayed by MMP9, MMP19, MMP25 and TIMP3 that 
define distinct regulatory mechanisms.  
 
Stimulation of PKC signaling by PMA led to enhanced accumulation of mRNA transcripts for 
eight MMP and two TIMP genes as early as 4 hours after stimulation in both MRC-5 and WI-38 
fibroblasts. Such accumulation may involve both transcriptional and post-transcriptional 
components (Yan and Boyd, 2007), and with regard to the former, roles for AP1 and Ets/PEA3 
transcription factors have been established for several genes including MMP1, MMP3, and 
TIMP1. These transcription factors can serve as focal points for convergence of MAPK signaling 
pathways (Benbow and Brinckerhoff, 1997; Westermarck and Kähäri, 1999). But since the 
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transcriptional activation of inducible MMP and TIMP genes takes place several hours after 
MAPK signaling has reached its peak, MAPK-mediated activation of pre-existing transcription 
factors may be insufficient. Activation of MAPKs leads to induction of c-fos and c-jun family 
members as IE response genes (Edwards and Mahadevan, 1992; Cano et al., 1994; reviewed in 
Hazzalin and Mahadevan, 2002) and evidence from gene knockout models or 
knockdown/overexpression systems has revealed an obligatory requirement for AP1 components 
for the transactivation of genes such as MMP1, MMP3 and TIMP1 (Hall et al., 2003; Hu et al., 
1994). Thus the obligation for protein synthesis could be understood in terms of a requirement for 
de novo production of AP1 in order to transactivate these MMPs and TIMP1 as downstream 
genes. However, not all PMA-inducible MMP/TIMP genes contain promoter-proximal AP1 sites, 
as is the case for MMP8 and MMP14 (Yan and Boyd, 2007), and TIMP2 contains such a site but is 
not inducible (Hammani et al., 1996). It is likely therefore that the requirement for protein 
synthesis that defines group I genes as late-activated involves several factors, among them AP1. 
 
Previous reports have shown that protein synthesis is required for induction of several MMP and 
TIMP genes in response to diverse stimuli, including: Timp1 induction in mouse fibroblasts by 
serum, PMA and transforming growth factor-β (Edwards et al., 1985; Hall et al., 2003; Young et 
al., 2005); Timp3 induction in mouse fibroblasts by PMA (Leco et al., 1994); Mmp3 induction in 
Rat-1 cells by epidermal growth factor (EGF; Matrisian et al., 1986); and Mmp9 induction in rat 
brain astrocytes by interleukin-1 beta (IL-1β; Wu et al., 2004). In human gastric epithelial 
tumours cells MMP1 induction by EGF and tumour necrosis factor–alpha (TNFα)/IL-1β requires 
protein synthesis, while MMP13 induction by TNFα/IL-1β does not (Pillinger et al., 2005). Our 
data represent the first systematic study, and demonstrate clearly that the use of multiple protein 
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synthesis inhibitors with different modes of action is essential in order to separate effects on 
translational arrest from cell signaling responses. Using emetine to block protein synthesis, the 
PMA-induction of MMP1, 3, 8, 9, 10, 12, 13, 14 and TIMP1 and TIMP3 was eliminated. With 
the exception of MMP9 and TIMP3, similar results were obtained using with anisomycin or 
cycloheximide. These inhibitors abrogated the requirement for protein synthesis for PMA-
induction, indicating a different mode of regulation for MMP9 and TIMP3, which we 
characterized as group II genes. Furthermore, anisomycin alone strongly induced TIMP3 
transcripts which was also the case for MMP25. As MMP25 was not PMA inducible, we infer 
that its regulation is distinct and thus we define it as a Group III gene. Since all three protein 
synthesis inhibitors cause polysome stabilization, the selective effects of anisomycin and 
cycloheximide on MMP9, TIMP3 and MMP25 mRNA levels are unlikely to be due simply to 
arrest of ribosome transit along the mRNAs. However, this could be the case for the group IV 
gene MMP19, which was not PMA inducible but whose transcripts accumulated when cells were 
exposed to all three protein synthesis inhibitors.  
 
To shed light on the selective effects of protein synthesis inhibitors on MMP and TIMP gene 
expression we analyzed their actions on MAPK signaling. Our data confirm selective pathway 
activation, with anisomycin activating the JNK and p38 pathways in MRC-5 and WI-38 but not 
the ERK-1/2 pathway, while cycloheximide stimulated only p38 in both cell types. We observed 
similar effects on MAPK activation in C3H10T½ and 3T3 (data not shown). Emetine (and 
puromycin, data not shown) did not induce appreciable activation of MAPKs in any cell type 
tested up to 1 hour of treatment. Also, as seen by others in C3H10T½ (Cano et al., 1994) and 
human skin fibroblasts (Westermarck et al., 2001), in MRC-5 and WI-38 cells, PMA activated 
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ERK-1/2 but not JNK and p38. These differential acute effects on MAPKs may therefore 
underpin inhibitor-specific effects on gene expression, and in particular the activation of stress 
pathways by both anisomycin and cycloheximide may be responsible for removal of the 
requirement for protein synthesis for PMA-induction of TIMP3 and MMP9, and the selective 
induction of MMP25 by anisomycin alone. 
 
Pharmacological inhibition of MEK-ERK signaling confirmed the centrality of this pathway in 
the PMA inducibility of all group I and II genes. However U0126 did not inhibit any of the 
selective effects of anisomycin and cycloheximide, which were sensitive to varying extents to 
either SB 203580 or SP600125: in particular, MMP25 induction by anisomycin was essentially 
eliminated by inhibition of either p38 or the JNK pathway. The JNK inhibitor SP600125 also 
significantly reduced anisomycin-mediated TIMP3 and MMP19 mRNA accumulation. However 
caution is required with this agent since although it shows preferential activity for JNKs among 
the MAPKs (Heo et al., 2004), it also efficiently inhibits other unrelated protein kinases 
including the p70 ribosomal protein S6 kinase and MAPKAP-K1a (Bain et al., 2003). Despite 
this caveat, which means that the use of more selective pathway inhibition strategies would be 
essential to determine the precise signaling components involved, the main message from these 
experiments is that cell signaling actions underlie the protein synthesis inhibitor-specific effects 
on MMP/TIMP gene expression, rather than inhibition of translation per se.  
 
It is clear that cell type-specific mechanisms will determine not only which MMP/TIMP genes 
are expressed but the signaling circuitry that controls them. For instance, anisomycin is a p38 
activator in many cells including neutrophils, mast cells and myocardial cells, but it does not 
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activate p38 in human platelets (Pampolina and McNicol, 1999), and in human osteosarcoma 
cells it activates all three MAPKs (Bébien et al., 2003). Further, in endothelial cells activation of 
JNK by anisomycin is sufficient to induce Mmp2 and Mmp14 expression and this requires c-Jun 
(Ispanovic and Hass, 2006). Cross-talk between the p38 and ERK pathways is also a relevant issue, 
since activation of MKK3→p38 α can block the ERK-1/2 pathway at the level of MEK-1/2 via 
protein phosphatase 1 and 2, thus inhibiting MMP1 gene expression (Westermarck et al., 2001) and 
p38 inhibition has been shown to promote ERK-1/2 phosphorylation (Munshi et al., 20004). Another 
important consideration is that all of the work reported here has involved analysis of steady state 
mRNA levels, which could reflect both transcriptional and post-transcriptional control 
mechanisms. Transcriptional induction likely plays a major role for the PMA-inducible group I 
genes since we have used a short timeframe for exposure to stimulation that would not allow 
effects of changes in mRNA stability to predominate; in our experience, MMP/TIMP transcripts 
are relatively long-lived mRNAs with half-lives of many hours (Overall et al., 1991; Leco et al., 
1994). However, there are several reports of post-transcriptional regulation of MMP genes 
(reviewed in Yan and Boyd, 2007) so it will be important to determine the contribution from 
post-transcriptional processes in future studies. This is particularly significant in relation to 
effects of p38 activation on MMP/TIMP expression, since this pathway is known to stabilize the 
transcripts of inflammation-associated genes via effects on AU-rich element binding protein 
functions (Dean et al., 2003). 
 
In summary our comprehensive survey of MMP and TIMP gene expression in human fibroblasts 
has identified common and unique patterns of regulation, which are summarized in Fig. 4. A 
major group of the genes share late induction kinetics that involve PMA-mediated activation of 
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the ERK MAPK pathway and a requirement for protein synthesis. However, our data emphasize 
the importance of consideration of the effects of protein synthesis inhibitors on stress signaling 
pathways, since for MMP9 and TIMP3 this was found to abrogate the requirement for protein 
synthesis for activation. Expansion of these datasets by survey of additional stimuli and in a 
variety of cellular backgrounds will facilitate bioinformatic analysis of gene regulatory elements 
that mediate particular aspects of transcriptional or post-transcriptional control. The evolutionary 
relationships of the members of the MMP and TIMP gene families make these genes particularly 
conducive to this type of analysis. 
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4. Experimental Procedures 
 
4. 1 Cell lines and treatments 
Human fetal lung MRC-5 and WI-38 fibroblasts were cultured in Minimal Essential Medium with 10% 
fetal bovine serum, 1% L-Glutamine, 1% non-essential amino acids, 1000 IU/ml penicillin and 100 µg/ml 
of streptomycin (all cell culture reagents from Invitrogen Life Sciences, Paisley, UK). Cells were 
maintained at 37oC and 5% (v/v) CO2. To assess if protein synthesis was necessary for PMA-induction, 
confluent cells were incubated overnight in serum-free medium followed by stimulation with 10 µg/ml of 
protein synthesis inhibitors and/or 100 nM of PMA for 8 hours (all from Sigma Aldrich, Poole, UK). To 
investigate the signalling pathways involved, confluent cells were seeded overnight in serum-free medium 
and treated with signalling inhibitors (U0126, SB 203580, SP600125 and Bisindolylmaleimide I) for 30 
minutes. The concentrations of the signaling pathways inhibitors used were 10 µM of U0126 (Promega, 
Madison, WI); 1 µM of SB 203580 (Sigma); 20 µM of SP600125 (Sigma) and 360 nM of 
Bisindolylmaleimide I (Calbiochem-Novabiochem Ltd, Beeston, UK). After 30 minutes of treatment with 
these inhibitors cells were stimulated with 100 nM of PMA, 10 µg/ml of anisomycin, emetine or 
cycloheximide for 8 hours. For analysis of MAPK activation by western blotting, confluent cells were 
incubated overnight in serum-free medium followed by treatment with 100 nM of PMA or 10 µg/ml 
proteins synthesis inhibitors for 5, 15, 30 and 60 minutes. 
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4.2 RNA isolation 
At the appropriate time points, cells were washed with cold phosphate buffered saline and total RNA was 
harvested using SV Total RNA isolation System (Promega) according to the instructions of the supplier. 
RNA was resuspended in RNase free water and stored at –80oC. The quality and the quantity of RNA 
were established by reading the optical density of each sample at 260 nm and 280 nm using a NanoDrop 
ND-1000 spectrophotometer (Labtech International Ringmer, UK). 
 
4.3 Reverse transcription 
RNA was pre-incubated with random hexamer primers at 70oC for 10 minutes and the reverse 
transcription reaction was performed at 42 oC for 60 minutes. Reverse transcription reactions contained 1 
µg of total RNA, 4x PCR buffer (Invitrogen), 1 mM deoxynucleotide triphospates dATP, dGTP, dCTP 
and dTTP (Roche Diagnostics Ltd, East Sussex, UK), 40 units Rnase Inhibitor (Promega), 2µl DTT 
(Invitrogen), 100 pmol of random hexamer primers (Promega) and 200 units of Super script II reverse 
transcriptase (Invitrogen). cDNA were stored at -20 oC. 
 
4.4 Quantitative real-time PCR 
QPCR was performed using the ABI PRISM 7700 Sequence Detection System (Applied Biosystems, 
Foster City, CA); reaction conditions and primer and probe sequences are described elsewhere (Nuttall et 
al., 2003). 18S rRNA (primers and probe from Applied Biosystems) was used as an endogenous control. 
Standard curves were prepared by serial dilutions and the relative quantity of the experimental samples 
was determined and divided by the quantity of endogenous control. The quantities of the samples were 
then expressed as a fold difference relative to unstimulated control at time 0. 
 
4.5 Western blot analysis 
Confluent cells were lysed using NP-40 lysis buffer (Sigma), containing protease inhibitor complete mini 
EDTA-free (Roche) and phosphatase inhibitor cocktail set II (Calbiochem). Protein quantities were 
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determined using BCA protein assay (Perbio Science Ltd, UK), and equal amounts in reducing loading 
buffer were electrophoresed in 10% polyacrylamide gels and transferred onto nitrocellulose membrane 
(Hybond ECL, Amersham Life Sciences). Efficiency of transfer was determined by Coomassie brilliant 
blue staining of the gels after electrotransfered and by Ponceau-S staining of the membranes after 
detection. Blots were probed with primary rabbit anti-human: ERK-1/2, phospho-ERK-1/2, JNK, 
phospho-JNK, p38, phospho-p38 and β–actin (all from New England Biolabs, Ipswich, MA) and 
secondary HRP-conjugated anti-rabbit (Vector Laboratories Inc., Burlingame, CA) according to supplier 
instructions.  
 
4.6 Measurement of total protein synthesis by 3H –Leucine incorporation 
Confluent MRC-5 cells were incubated overnight in serum-free medium, then 5 µCi of  3H-Leucine 
(Amersham) was added following of treatment with protein synthesis inhibitors 10 µg/ml or 100 nM of 
PMA for 8 hours. At the appropriate time point, cells were washed three times with cold Hank’s Balanced 
Salts Solution (Invitrogen), fixed at 4oC for 5 minutes with 10% tricholoroacetic acid, washed with 
methanol and allowed to dry. Cells were then lysated using 0.3 M NaOH, 1% SDS for 30 min with gentle 
shaking at room temperature. Lysates were mixed and transferred to scintillation vials containing of 
Optiphase ‘Super mix’ scintillation fluid: (PerkinElmer LAS Ltd, UK). Protein synthesis was quantified 
determining incorporated radioactivity by liquid scintillation counting in the Wallac System 1400TM 
(PerkinElmer). 
 
4.7 Assay for cell viability 
Cells were seeded at 10,000 and 20,000 cells per well in a 96-well plate overnight, followed by treatment 
with PMA, protein synthesis inhibitors, U0126, SB 203580, SP600125 and Bisindolylmaleimide I at the 
identical concentrations and times used for qPCR analysis. To assess the number of viable cells after 4 
hours of treatment methylthiazoletetrazolium (MTT, Sigma) was added and cells were incubated for 
additional 4, 8 or 20 hours. Then the medium was removed and the resulting precipitate was dissolved in 
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dimethyl sulphoxide. The intensity of the colour was determined by spectrophotometric measurement of 
the samples at 550 nm with a reference wavelength at 690 nm, using an MRX spectrophotometer 
(Dynatech Laboratories, Chantilly, VA, USA). Cell viability was quantified determining as percent over 
the control samples. 
 
4.8 Statistical Analysis 
Standard curves were used to convert cycle threshold (CT) data from qPCR analysis to relative RNA 
levels, and all statistics were done on these values normalized to 18S rRNA. Statistical test were done 
using SigmaStat (SPSS Inc.), while clustering by Spearman rank, to classify groups of genes according 
PMA and protein synthesis inhibitors effect, was done using Cluster version 2.11 (Eisen et al., 1998). 
Students t-test was used to examine the differences between control and PMA stimulated samples. To 
compare the effect of PMA with or without protein synthesis inhibitors, two way analysis of variance 
between groups (ANOVA) test was used following a log transformation of the data. In these tests, a p 
<0.05 was considered significant. To compare MRC-5 and WI-38 cells types, Spearman correlation was 
used a positive coefficient (rs>0.5) with p <0.05 was considered significant. To asses the effect of 
pharmacological inhibitors on PMA and anisomycin induction one way ANOVA was used following a 
log transformation of the data, with separate test for PMA and anisomycin. In these tests, a p <0.05 was 
considered significant. 
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Figure Legends 
 
Fig. 1. Effect of protein synthesis inhibitors on blocking translation and effect of protein synthesis 
inhibitors in the presence or absence of PMA on selected MMP and TIMP expression.  
A, MRC-5 cells were serum starved for 18 hours, 3H-Leucine was added to the medium and then cells 
were stimulated with 100 nM of PMA and/or 10 µg/ml protein synthesis inhibitors: anisomycin, emetine 
and cycloheximide for 8 hours. Levels of new protein synthesis were evaluated as the 3H-leucine 
incorporation. Results are plotted as average and range of samples relative 3H-leucine incorporation to 
control samples. B-F, MRC-5 cells were serum starved for 18 hours, then stimulated with 10 µg/ml of 
anisomycin, emetine and cycloheximide in presence or absence 100 nM of PMA for 8 hours. Total RNA 
was isolated and subjected qPCR analysis of every MMP and TIMP gene; data were normalized to 18S 
rRNA. Shown are genes representative of group I, B, MMP1, and C, TIMP1; group II, D, TIMP3; group 
III, E, MMP25; and group IV, F, MMP19. White and black bars represent time 0 and time 8 respectively. 
Data is representative of at least two experiments in all cases. Error bars represent the mean + SEM, n = 
3. *,** or *** represent significant difference (p <0.05, <0.01, or <0.001, respectively) compared to 
unstimulated at 8 hours; #, ##, or ### represent significant difference (p <0.05, <0.01, or <0.001, 
respectively) compared to the PMA treatment alone. 
 
Fig. 2. Effect of PMA and protein synthesis inhibitors on the activation of the main MAPKs and the 
MMPs and TIMPs.  
MRC-5 cells were stimulated with 100 nM of PMA or 10 µg/ml protein synthesis inhibitors: anisomycin, 
emetine or cycloheximide for times as indicated. Levels of activated ERK-1/2, JNK-1/2 and p38 were 
determined by western blot analysis using phospho-specific antibodies. Levels of total ERK-1/2, JNK-1/2 
and p38 were assessed following stripping of the membrane corresponding to the phospho MAPK. β–
actin antibody was used as a loading control. Results are representative of at least two independent 
experiments done by duplicate.  
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Fig. 3. Effect of pharmacological inhibitors in response to PMA and anisomycin of selected MMP 
and TIMP genes in MRC-5 fibroblasts.  
MRC-5 cells were serum starved for 18 hours, followed by treatment with 10 µM of U0126; 1 µM of SB 
203580; 20 µM of SP600125 or 360 ηM of Bisindolylmaleimide I for 30 minutes. Cells were then treated 
with 100 nM of PMA or 10 µg/ml of anisomycin for 8 hours. Total RNA was isolated and subjected to 
qPCR analysis. Shown are representative genes of group I, A, MMP1, B, MMP10 and C, TIMP1; group II, 
D, TIMP3; group III, E, MMP25 and group IV, F, MMP19. White and black bars represent time 0 and 
time 8 respectively. Results are representative of two independent experiments. Error bars represent the 
mean + SEM, n = 3. *, **, or *** represent significant difference (p <0.05, <0.01, or <0.001, 
respectively) compared to PMA alone; #, ##, or ### represent significant difference (p <0.05, <0.01, or 
<0.001, respectively) compared to the anisomycin treatment alone. 
 
Fig. 4 Proposed model of MMP and TIMP regulation by PMA and anisomycin.  
Our current studies indicate that anisomycin activate both p38 and JNK and PMA activate ERK-1/2 via 
PKC in fibroblasts. As shown in the model, activation of MAPK pathways results in stimulation at 
transcriptional level of select  MMP and TIMP genes, which was confirmed using MAPK 
pharmacological inhibitors. According to their response to PMA and anisomycin the MMP and TIMP 
genes were classified in groups as indicated (groups I-IV). Barbed arrows indicate stimulation and blunt 
ended lines, inhibition. 
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Table 1 
 
Level of basal 
expression 
PMA-responsive  PMA-unresponsive 
 Very high 
CT ≤ 25 
 MMP1# 
MMP14* 
TIMP1* 
TIMP3* 
 MMP2 
MMP11 
TIMP2 
 High 
CT = 26-30 
 MMP3# 
MMP10# 
 MMP15 
MMP16 
MMP17 
MMP19 
MMP23 
MMP24 
TIMP4 
 Moderate 
CT = 31-35 
   MMP28 
 Low 
CT = 36-39 
 MMP8* 
MMP12* 
 MMP7 
MMP21 
MMP25 
MMP26 
MMP27 
 Not detected 
CT = 40 
 MMP9 
MMP13 
 MMP20 
 
 
Table 1. Relative mRNA levels and PMA-responsiveness for the entire MMP and TIMP family in 
MRC-5. Classification of expression levels was determined from the CT of each gene under basal 
conditions as very high (CT ≤ 25), high (CT = 26-30), moderate (CT = 31-35), low (CT = 36-39) or not 
detected (CT = 40). To determine the effect of PMA MRC-5 cells were treated with 10-7 M PMA for 8 
hours.* 2-10 fold above basal expression, # > 10 fold above basal expression. 
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